NDATOPICALOINTMENT
Approved
Oct 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
CORDRAN (flurandrenolide) by Molecular Devices is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1965.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORDRAN (flurandrenolide) is a mid-potency topical corticosteroid ointment approved in 1965 for inflammatory and pruritic skin conditions. It works by binding to corticosteroid hormone receptors to reduce inflammation, itching, and skin irritation. The drug is administered topically and remains a standard dermatology treatment despite its age.
$0.003BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal market spending ($3M), indicating a mature, commoditized asset with reduced team investment opportunities.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CORDRAN is not actively driving pharma career growth; the product supports legacy roles in dermatology marketing and access but does not create new team expansions or specialized positions. Career value lies in cost optimization and brand defense rather than innovation or growth.
Company
Worked on CORDRAN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.